Inhibition of p38 mitogen-activated protein kinase attenuates experimental autoimmune hepatitis: Involvement of nuclear factor kappa B

World Journal of Gastroenterology

Volumn 13, Issue 31, 2007, Pages 4249-4254

  Ma, Xiong ^a   Jia, Yi Tao ^a   Qiu, De Kai ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Autoimmune hepatitis; Nuclear factor kappa B; p38 mitogen activated protein kinase; Proinflammatory cytokines

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALANINE AMINOTRANSFERASE; ANTIGEN; CYTOKINE; DNA; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROTEIN S 100; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; HISTOLOGY; LIVER INJURY; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PROTEIN DNA BINDING; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 34548502193     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i31.4249     Document Type: Article

References (36)

1. Strassburg CP, Manns MP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 2002; 22: 339-352
2. Schramm C, Protschka M, Kohler HH, Podlech J, Reddehase MJ, Schirmacher P, Galle PR, Lohse AW, Blessing M. Impairment of TGF-beta signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice. Am J Physiol Gastrointest Liver Physiol 2003; 284: G525-G535
3. Lohse AW, Manns M, Dienes HP, Meyer zum Buschenfelde KH, Cohen IR. Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology 1990; 11: 24-30
4. Kohda H, Sekiya C, Kanai M, Yoshida Y, Uede T, Kikuchi K, Namiki M. Flow cytometric and functional analysis of mononuclear cells infiltrating the liver in experimental autoimmune hepatitis. Clin Exp Immunol 1990; 82: 473-478
5. Lohse AW, Brunner S, Kyriatsoulis A, Manns M, Meyer zum Buschenfelde KH. Autoantibodies in experimental autoimmune hepatitis. J Hepatol 1992; 14: 48-53
6. Lohse AW, Dienes HP, Meyer zum Buschenfelde KH. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or inummosuppression. Hepatology 1998; 27: 1536-1543
7. Jaeckel E. Animal models of autoimmune hepatitis. Semin Liver Dis 2002; 22: 325-38
8. Wang XS, Diener K, Manthey CL, Wang S, Rosenzweig B, Bray J, Delaney J, Cole CN, Chan-Hui PY, Mantlo N, Lichenstein HS, Zukowski M, Yao Z. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J Biol Chem 1997; 272: 23668-23674
9. Nakamura H, Kawakami A, Yamasaki S, Kawabe Y, Nakamura T, Eguchi K. Expression of mitogen activated protein kinases in labial salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis 1999; 58: 382-385
10. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, Zenz P, Redlich K, Xu Q, Steiner G. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2501-2512
11. Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M. Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J 2004; 18: 1550-1552
12. Twata Y, Wada T, Furuichi K, Sakai N, Matsushima K, Yokoyama H, Kobayashi K. p38 Mitogen-activated protein kinase contributes to autoimmune renal injury in MRL-Fas lpr mice. J Am Soc Nephrol 2003; 14: 57-67
13. Aroor AR, Shukla SD. MAP kinase signaling in diverse effects of ethanol. Life Sci 2004; 74: 2339-2364
14. Panteva M, Korkaya H, Jameel S. Hepatitis viruses and the MAPK pathway: is this a survival strategy? Virus Res 2003; 92: 131-140
15. Tsutsumi T, Suzuki T, Moriya K, Shintani Y, Fujie H, Miyoshi H, Matsuura Y, Koike K, Miyamura T. Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology 2003; 38: 820-828
16. Gilbert KM, Whitlow AB, Pumford NR. Environmental contaminant and disinfection by-product trichloroacetaldehyde stimulates T cells in vitro. Int Immunopharmacol 2004; 4: 25-36
17. Griffin JM, Gilbert KM, Lamps LW, Pumford NR. CD4(+) T-cell activation and induction of autoimmune hepatitis following trichloroethylene treatment in MRL+/+ mice. Toxicol Sci 2000; 57: 345-352
18. Ma X, Qiu D, Peng Y, Chen X. [Expression of neural cell adhesion molecule in murine livers with experimental autoimmune hepatitis. Zhonghua Ganzangbing Zazhi 2001; 9: 226-228
19. Ma X, Qiu DK, Li EL, Peng YS, Chen XY. [Effect of T-cell vaccination in murine experimental autoimmune hepatitis] Zhonghua Ganzangbing Zazhi 2004; 12: 44-46
20. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002; 6: 727-737
21. Chernavsky AC, Paladino N, Rubio AE, De Biasio MB, Periolo N, Cuarterolo M, Goni J, Galoppo C, Canero-Velasco MC, Munoz AE, Fainboim H, Fainboim L. Simultaneous expression of Th1 cytokines and IL-4 confers severe characteristics to type I autoimmune hepatitis in children. Hum Immunol 2004; 65: 683-691
22. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000; 12: 1-13
23. Perregaux DG, Dean D, Cronan M, Connelly P, Gabel CA. Inhibition of interleukin-1 beta production by SKF86002: evidence of two sites of in vitro activity and of a time and system dependence. Mol Pharmacol 1995; 48: 433-442
24. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372: 739-746
25. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004; 4: 372-377
26. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002; 20: 55-72
27. Al-Khalidi JA, Czaja AJ. Current concepts in the diagnosis, pathogenesis, and treatment of autoimmune hepatitis. Mayo Clin Proc 2001; 76:1237-1252
28. Hussain MJ, Mustafa A, Gallati H, Mowat AP, Mieli-Vergani G, Vergani D. Cellular expression of tumour necrosis factor-alpha and interferon-gamma in the liver biopsies of children with chronic liver disease. J Hepatol 1994; 21: 816-821
29. Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999; 117: 645-652
30. Cookson S, Constantini PK, Clare M, Underhill JA, Bernal W, Czaja AJ, Donaldson PT. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999; 30: 851-856
31. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87: 13-20
32. Sun Z, Andersson R. NF-kappaB activation and inhibition: a review. Shock 2002; 18: 99-106
33. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-6866
34. Conner EM, Brand S, Davis JM, Laroux FS, Palombella VJ, Fuseler JW, Kang DY, Wolf RE, Grisham MB. Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther 1997; 282: 1615-1622
35. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, Lazarus D, McCormack T, Parent L, Stein R, Adams J, Grisham MB. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998; 95: 15671-15676
36. Baeza-Raja B, Munoz-Canoves P. p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: Tole of interleukin-6. Mol Biol Cell 2004; 15: 2013-2026